B
Bicara Therapeutics
A clinical-stage company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators.
About Bicara Therapeutics
Bicara operates in the biotechnology sector, focusing on the development of innovative therapies for cancer treatment. The company combines the precision of targeted therapies with the power of tumor modulators to create dual-action treatments. Bicara serves patients and healthcare providers in the oncology market, aiming to improve patient outcomes through advanced therapeutic solutions. The business model revolves around research and development, clinical trials, and eventual commercialization of its therapies. Revenue is generated through partnerships, licensing agreements, and sales of approved treatments. Key clients include hospitals, cancer treatment centers, and pharmaceutical companies. The company leverages a strong team with extensive experience in regulatory affairs and drug development to navigate the complex landscape of healthcare regulations and bring its therapies to market efficiently.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Cambridge, United States
- Listing
- IPO 2024
- Employees
- 117
- Open positions
- 27
- Dealroom signal
- 60.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Bicara Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Feb 2026 | $150M | — | Undisclosed | ↗ |
| IPOOther financing | Sep 2024 | $362M | $362M | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$155M | — |
| 2025 | $0 | — | −$155M | — |
| 2024 | $0 | — | −$82M | — |
| 2023 | $0 | — | −$52M | — |
| 2022 | $0 | — | −$38M | — |
Growth signals
Latest recorded traffic for Bicara Therapeutics is 20K monthly website visits, up 81.8% over the last three months. Bicara Therapeutics's team grew 24.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Biocon
Series A11 investors entered at this stage
Premji Invest
Invus
Omega Funds
Bioqube Ventures
Red Tree Venture Capital- PCPiper Heartland Healthcare Capital
Eight Roads Ventures
F-Prime
RA Capital Management
Janus Henderson Investors
Acorn Bioventures
Series B and later6 investors entered at this stage
TPG
Aisling Capital
The Rise Fund (TPG)
Braidwell
Deerfield
Fairmount Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Bicara Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Bicara Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.